Evolution of CRISPR-enabled biosensors for amplification-free nucleic acid detection

Sepehr Talebian¹, Fariba Dehghani², Paul S Weiss³, João Conde⁴

Affiliations

¹ School of Chemical and Biomolecular Engineering, The University of Sydney, Sydney, NSW 2006, Australia; Nano Institute (Sydney Nano), The University of Sydney, Sydney, NSW 2006, Australia. Electronic address: sepehr.talebian@sydney.edu.au.
² School of Chemical and Biomolecular Engineering, The University of Sydney, Sydney, NSW 2006, Australia; Nano Institute (Sydney Nano), The University of Sydney, Sydney, NSW 2006, Australia.
³ California NanoSystems Institute, University of California, Los Angeles, Los Angeles, CA 90095, USA; Department of Chemistry and Biochemistry, University of California, Los Angeles, Los Angeles, CA 90095, USA; Department of Bioengineering, University of California, Los Angeles, Los Angeles, CA 90095, USA; Department of Materials Science and Engineering, University of California, Los Angeles, Los Angeles, CA 90095, USA.
⁴ ToxOmics, NOVA Medical School, Faculdade de Ciências Médicas, NMS, FCM, Universidade NOVA de Lisboa, 1169-056 Lisbon, Portugal. Electronic address: joao.conde@nms.unl.pt.

PMID: 37516612
DOI: 10.1016/j.tibtech.2023.07.004

Evolution of CRISPR-enabled biosensors for amplification-free nucleic acid detection

Sepehr Talebian et al. Trends Biotechnol. 2024 Jan.

. 2024 Jan;42(1):10-13.

doi: 10.1016/j.tibtech.2023.07.004. Epub 2023 Jul 27.

Authors

Sepehr Talebian¹, Fariba Dehghani², Paul S Weiss³, João Conde⁴

Affiliations

¹ School of Chemical and Biomolecular Engineering, The University of Sydney, Sydney, NSW 2006, Australia; Nano Institute (Sydney Nano), The University of Sydney, Sydney, NSW 2006, Australia. Electronic address: sepehr.talebian@sydney.edu.au.
² School of Chemical and Biomolecular Engineering, The University of Sydney, Sydney, NSW 2006, Australia; Nano Institute (Sydney Nano), The University of Sydney, Sydney, NSW 2006, Australia.
³ California NanoSystems Institute, University of California, Los Angeles, Los Angeles, CA 90095, USA; Department of Chemistry and Biochemistry, University of California, Los Angeles, Los Angeles, CA 90095, USA; Department of Bioengineering, University of California, Los Angeles, Los Angeles, CA 90095, USA; Department of Materials Science and Engineering, University of California, Los Angeles, Los Angeles, CA 90095, USA.
⁴ ToxOmics, NOVA Medical School, Faculdade de Ciências Médicas, NMS, FCM, Universidade NOVA de Lisboa, 1169-056 Lisbon, Portugal. Electronic address: joao.conde@nms.unl.pt.

PMID: 37516612
DOI: 10.1016/j.tibtech.2023.07.004

Abstract

CRISPR biosensors enable rapid and accurate detection of nucleic acids without resorting to target amplification. Specifically, these systems facilitate the simultaneous detection of multiple nucleic acid targets with single-base specificity. This is an invaluable asset that can ultimately facilitate accurate diagnoses of biologically complex diseases.

Keywords: CRISPR/Cas; amplification-free; biosensing; nucleic acid detection.

PubMed Disclaimer

Conflict of interest statement

Declaration of interests J.C. is a co-founder and shareholder of TargTex SA targeted therapeutics for glioblastoma multiforme. The other authors declare no competing interests.

MeSH terms

Actions
Actions
Actions
Actions
Actions

Substances

Actions

Grants and funding

ERC-STG-2019-848325)/ERC_/European Research Council/International

LinkOut - more resources

Full Text Sources
- ClinicalKey
- Elsevier Science

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Evolution of CRISPR-enabled biosensors for amplification-free nucleic acid detection

Affiliations

Evolution of CRISPR-enabled biosensors for amplification-free nucleic acid detection

Authors

Affiliations

Abstract

Conflict of interest statement

MeSH terms

Substances

Grants and funding

LinkOut - more resources

Full Text Sources